SELLAS partners with IMPACT-AML for European SLS009 trial expansion Jan 14, 2026 08:31AM
Increasing unusual put option volume: SLS SPG CWAN CSGP NUAI LQDA AMT EXE IBRX CPRT SEI BUD Jan 5, 2026 05:32AM
Increasing unusual put option volume: SLS WMB NUAI RARE PPLT DBRG BTG HWM TECL UBS HYMC Dec 29, 2025 10:16AM
SELLAS Life Sciences Group, Inc. (SLS) Tops Q3 EPS by 2c Nov 12, 2025 04:34PM
SELLAS raises $31 million through warrant exercise by institutional investor Oct 27, 2025 08:30AM


Oct 13, 2025 08:02AM SELLAS to present preclinical data on SLS009 for leukemia at ESMO
Oct 10, 2025 04:08PM SELLAS Life Sciences (SLS) files for 19.7M share offering by selling stockholders
Sep 11, 2025 08:31AM SELLAS Life Sciences receives $23.6 million from warrant exercise
Aug 12, 2025 05:40PM SELLAS Life Sciences Group, Inc. (SLS) Tops Q2 EPS by 1c
Jul 7, 2025 08:45AM SELLAS (SLS) appoints Linghua Wang to scientific advisory board
Jun 24, 2025 08:00AM SELLAS Life Sciences (SLS) to be Added to Russell 3000® and Russell 2000 Indexes
Jun 5, 2025 08:45AM SELLAS Life Sciences (SLS) Adds Two Hematology and Oncology Experts to Advisory Board
Jun 2, 2025 08:01AM SELLAS Life Sciences (SLS) Presents Preclinical Efficacy of SLS009
May 15, 2025 08:45AM SELLAS Life Sciences (SLS) Announces First Pediatric AML Patient Dosed in the Ongoing Phase 2 Trial of SLS009 r/r AML
May 13, 2025 04:13PM SELLAS Life Sciences Group, Inc. (SLS) Tops Q1 EPS by 4c
Apr 28, 2025 08:45AM SELLAS Life Sciences (SLS) Unveils Preclinical Data Highlighting Efficacy of SLS009
Apr 8, 2025 08:45AM SELLAS Life Sciences (SLS) Announces Positive Overall Survival in Cohort 3 from the Ongoing Phase 2 Trial of SLS009 in r/r AML
Feb 20, 2025 08:45AM SELLAS Life Sciences (SLS) Announces Positive Data from Phase 2a Trial of SLS009 plus Zanubrutinib
Jan 28, 2025 03:12PM SELLAS Life Sciences (SLS) Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Jan 23, 2025 08:11AM SELLAS Life Sciences (SLS) Announces Positive Outcome of Interim Analysis for its Pivotal Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia
Jan 8, 2025 08:20AM SELLAS Life Sciences (SLS) Announces Key Business Objectives for 2025
Dec 10, 2024 08:32AM SELLAS Life Sciences (SLS) Triggers Interim Analysis in Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia
Dec 9, 2024 08:45AM SELLAS Life Sciences (SLS) Announces Positive Overall Survival and Overall Response Rate Data from the Phase 2 Trial of SLS009 in r/r AML
Nov 27, 2024 08:46AM SELLAS Life Sciences (SLS) Announces Positive Data from Preclinical Studies Indicating ASXL1 Mutations as Predictor of Response to SLS009 in Solid Cancers
Nov 13, 2024 05:51PM SELLAS Life Sciences Group, Inc. (SLS) Tops Q3 EPS by 3c
Oct 15, 2024 08:45AM SELLAS Life Sciences (SLS) Announces U.S. FDA Rare Pediatric Disease Designation Granted to Galinpepimut-S (GPS) for the Treatment of Pediatric Acute Myeloid Leukemia
Aug 13, 2024 05:11PM SELLAS Life Sciences Group, Inc. (SLS) Tops Q2 EPS by 4c
Aug 6, 2024 08:45AM SELLAS Life Sciences (SLS) Receives EMA Orphan Drug Designation for SLS009
Jul 31, 2024 08:31AM SELLAS Life Sciences (SLS) Announces 15.85M Share Offering at $1.325/sh
Jul 16, 2024 09:05AM SELLAS Life Sciences (SLS) Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to SLS009 for the Treatment of Pediatric Acute Myeloid Leukemia
Jul 8, 2024 08:46AM SELLAS (SLS) Receives European Medicines Agency Orphan Drug Designation for SLS009 for the Treatment of Acute Myeloid Leukemia
Jun 24, 2024 09:05AM SELLAS Life Sciences (SLS) Granted FDA Rare Pediatric Disease Designation for SLS009
Jun 18, 2024 08:45AM Treatment of Blood Cancers - Biopharma Companies Building out their Pipeline of Solutions
Jun 17, 2024 09:05AM SELLAS Life Sciences (SLS) Announces Positive Recommendation from the Independent Data Monitoring Committee of the Phase 3 REGAL Trial in AML